Have you observed any significant differences in treatment outcomes between these two therapies in your local practice?

What challenges do clinicians face in monitoring in disease progrission and response to therapy?

What factors influence your decision to switch a patient from alglucosidase alfa to avalglucosidase alfa?

How has avalglucosidase alfa impacted the treatment paradigm for both infantile-onset and late-onset Pompe disease in your experience?